Dean A. Lee
Immunology and Microbiology · The Ohio State University
Publications
478
Citations
13,919
Est. group size
~9
Recurring co-author estimate
Active years
39
Publishing since 1988
Dean A. Lee's research focuses on natural killer (NK) cells and engineered immune cell therapies, particularly CAR-NK (chimeric antigen receptor-modified natural killer) cells, for treating cancers such as leukemia, sarcoma, and other blood and solid tumors. The work spans laboratory cell engineering and manufacturing methods through to clinical and translational studies, including combination therapies with antibodies and cytokine agonists to improve tumor-killing effectiveness.
Publication output has remained fairly steady over the past decade, averaging about 29 papers per year in the last five years, with a notable spike in 2023.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody
Journal for ImmunoTherapy of Cancer · 2026
- Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group
Blood Advances · 2025
- Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy
Cytotherapy · 2025
- High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
Blood · 2025
- Natural killer cells in skin: a unique opportunity to better characterize the many facets of an overlooked secondary lymphoid organ
Frontiers in Immunology · 2025
- CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma
Molecular Therapy Oncology · 2025
- GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia
Cytotherapy · 2025
- Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignancies
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Abstract 6283: Performance evaluation of tumor microenvironment deconvolution and gene prediction methods in lung cancer
Cancer Research · 2025
- Enhancing CD33.CAR NK cell therapy for acute myeloid leukemia through TGFβ imprinting and NKTR-255
Blood · 2025
- DNA methylation of RPS6KA2 gene impacts the early persistent phenotype of food allergy: COCOA study
Journal of Allergy and Clinical Immunology · 2025
- Abstract No. 273 Safety and Efficacy of Primary Stent Placement for Hepatic Artery Kinks in Liver Transplant Recipients
Journal of Vascular and Interventional Radiology · 2025
- Targeting Ewing Sarcoma By IL1RAP CAR Modified Ex-Vivo Expanded TGFβ Imprinted NK Cells in Combination with IL-15 Agonist and Anti-GD2 Antibody
Transplantation and Cellular Therapy · 2025
- Bringing in cytokine support troops with an OV Trojan horse
Molecular Therapy Oncology · 2025
- Avidity engineered multifunctional antibodies for stimulation and orchestration of innate and adaptive immune cells in tumor tissues.
Journal of Clinical Oncology · 2025
- Blood×45
- Transplantation and Cellular Therapy×20
- Biology of Blood and Marrow Transplantation×18
- Cancer Research×15
- Journal of Clinical Oncology×13
- Jianhua Yu
Immunology and Microbiology · The Ohio State University
- Kenneth J. Oestreich
Immunology and Microbiology · The Ohio State University
- Hsiaoyin Mao
Immunology and Microbiology · The Ohio State University
- Jilu Zhang
Immunology and Microbiology · Indiana University
- Kyle B. Lupo
Immunology and Microbiology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile